GlobalData on MSN14h
AnaptysBio achieves ‘highest ever’ results in Phase II rheumatoid arthritis trial
AnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ...
Telehealth may be closing the care gap for people with substance use disorder in rural areas
Recognition of telehealth as an effective strategy for delivering treatment for substance use disorder (SUD) has raised hopes for improving access to this treatment in settings with limited ...
Investor's Business Daily on MSN17h
AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment
AnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.
Dear Doctor: I’m concerned colonoscopy anesthesia will affect husband’s already compromised short-term memory
ANSWER: Both RA and MCTD are rheumatologic diseases that affect many systems of the body. MCTD is often considered an overlap ...
FierceBiotech18h
AnaptysBio's PD-1 drug reduces rheumatoid arthritis in phase 2 trial
AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.
AnaptysBio stock soars on positive RA trial results
The positive trial results have not only demonstrated rosnilimab's potential in treating RA but have also validated AnaptysBio's scientific approach in targeting PD-1 co-inhibitory receptors on ...